FDA gives arGentis treatment 'orphan' designation - Bizjournals.com
 CTV.ca | FDA gives arGentis treatment 'orphan' designation Bizjournals.com - Memphis-based arGentis Pharmaceuticals LLC's systemic sclerosis, or scleroderma, treatment has been given orphan drug designation by the Food and Drug Administration. FDA Bowed to Drug Company Pressure in Reassigning Reviewer Senate inquiry rebukes FDA: 'scientific process ... compromised' |